Theralase Technologies shares positive interim results from Phase II Bladder Cancer study

(NewsDirect)

Theralase Technologies CEO Roger DuMoulin-White joined Steve Darling from Proactive to share interim data from a Phase II clinical study designed to treat patients diagnosed with Bacillus Calmette-Guérin Unresponsive, Non-Muscle Invasive Bladder Cancer and Carcinoma In-Situ with a patented investigational study drug Ruvidar, subsequently activated by a proprietary investigational study laser system equipped with fiber-optic light emitters and detectors.

DuMoulin-White discussed more about the study and what the interim data is telling them about the study.

He also talked about the company and the other vertical it has with its Cool Laser Therapy which is focused on the research, development, production and distribution of medical laser technologies for healing pain.

Contact Details

Proactive Investors

+1 604-688-8158

[email protected]

Copyright (c) 2023 TheNewswire - All rights reserved.